Brought to you by 
Oncologie closes $80mm Series B round
10 Jun 2019
Executive Summary
Oncologie Inc. (biologics and small-molecule therapies for cancer) raised $80mm through its Series B round from Nan Fung Life Sciences and Pivotal BioVentures China (co-leads), along with a syndicate of new investors including Panacea Venture Healthcare and Korea Investment Partners. Proceeds will support continued development of the company's three clinical projects for solid tumors (bavituximab, lefitolimod, and varisacumab), and will also go towards in-licensings and development of a biomarker platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncologie closes $80mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice